PL357261A1 - Leczenie zastoinowej niewydolności serca wstępnietraktowaną krwią autologiczną - Google Patents

Leczenie zastoinowej niewydolności serca wstępnietraktowaną krwią autologiczną

Info

Publication number
PL357261A1
PL357261A1 PL01357261A PL35726101A PL357261A1 PL 357261 A1 PL357261 A1 PL 357261A1 PL 01357261 A PL01357261 A PL 01357261A PL 35726101 A PL35726101 A PL 35726101A PL 357261 A1 PL357261 A1 PL 357261A1
Authority
PL
Poland
Prior art keywords
treatment
heart failure
congestive heart
autologous blood
pretreated
Prior art date
Application number
PL01357261A
Other languages
English (en)
Inventor
Eldon R. Smith
Guillermo Torre-Amione
Original Assignee
Vasogen Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasogen Ireland Limited filed Critical Vasogen Ireland Limited
Publication of PL357261A1 publication Critical patent/PL357261A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
PL01357261A 2000-01-18 2001-01-18 Leczenie zastoinowej niewydolności serca wstępnietraktowaną krwią autologiczną PL357261A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2296997 CA2296997A1 (en) 2000-01-18 2000-01-18 Treatment of congestive heart failure
PCT/CA2001/000039 WO2001052870A1 (en) 2000-01-18 2001-01-18 Treatment of congestive heart failure by pretreated autologous blood

Publications (1)

Publication Number Publication Date
PL357261A1 true PL357261A1 (pl) 2004-07-26

Family

ID=4165156

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01357261A PL357261A1 (pl) 2000-01-18 2001-01-18 Leczenie zastoinowej niewydolności serca wstępnietraktowaną krwią autologiczną

Country Status (24)

Country Link
US (3) US6572895B2 (pl)
EP (1) EP1267897B1 (pl)
JP (1) JP2003520244A (pl)
KR (1) KR100543413B1 (pl)
CN (1) CN1173710C (pl)
AT (1) ATE281839T1 (pl)
AU (1) AU773118B2 (pl)
BR (1) BR0107705A (pl)
CA (2) CA2296997A1 (pl)
CZ (1) CZ20022402A3 (pl)
DE (1) DE60107065T2 (pl)
DK (1) DK1267897T3 (pl)
EA (1) EA005011B1 (pl)
ES (1) ES2232632T3 (pl)
HK (1) HK1050847B (pl)
IL (1) IL150725A0 (pl)
MX (1) MXPA02007032A (pl)
NO (1) NO20023267L (pl)
NZ (1) NZ520083A (pl)
PL (1) PL357261A1 (pl)
PT (1) PT1267897E (pl)
TR (1) TR200201822T2 (pl)
WO (1) WO2001052870A1 (pl)
ZA (1) ZA200205401B (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040199209A1 (en) * 2003-04-07 2004-10-07 Hill Michael R.S. Method and system for delivery of vasoactive drugs to the heart prior to and during a medical procedure
US6904318B2 (en) * 2000-09-26 2005-06-07 Medtronic, Inc. Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure
US6449507B1 (en) * 1996-04-30 2002-09-10 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
US7269457B2 (en) * 1996-04-30 2007-09-11 Medtronic, Inc. Method and system for vagal nerve stimulation with multi-site cardiac pacing
US6628987B1 (en) * 2000-09-26 2003-09-30 Medtronic, Inc. Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia
US8036741B2 (en) 1996-04-30 2011-10-11 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US6479523B1 (en) * 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
US7840278B1 (en) * 1999-06-25 2010-11-23 Puskas John D Devices and methods for vagus nerve stimulation
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure
US6516121B2 (en) * 2000-04-26 2003-02-04 Interconnect Technology Llc Configuring optical fibers in a multi-chip module
US6487446B1 (en) * 2000-09-26 2002-11-26 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
CA2327631A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Inflammatory cytokine secretion inhibition
WO2003086503A2 (en) * 2002-04-10 2003-10-23 Vasogen Ireland Limited Electrocardiographic aspects of chf treatment
US7255880B2 (en) * 2003-04-03 2007-08-14 Vasogen Ireland Limited Treatment of endothelin-related disorders
US20100316727A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of inflammatory disorders with ozone
US20100318014A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of acute ischemic brain stroke with ozone
US20100316730A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of cardiovascular diseases with ozone
US20060095102A1 (en) * 2003-09-17 2006-05-04 Thomas Perez Method and apparatus for sublingual application of light to blood
US20050100964A1 (en) * 2003-11-11 2005-05-12 George Jackowski Diagnostic methods for congestive heart failure
WO2005097145A1 (en) * 2004-04-12 2005-10-20 Vasogen Ireland Limited Myocarditis treatment
WO2008000067A1 (en) * 2006-06-26 2008-01-03 Vasogen Ireland Limited Treatment of mild chronic heart failure in human patients
CA2679178A1 (en) * 2007-02-26 2008-09-04 Mount Sinai Hospital Compositions and methods for treating peripheral vascular diseases
US8200308B2 (en) * 2007-07-18 2012-06-12 Siemens Medical Solutions Usa, Inc. Continuous measurement and mapping of physiological data
CN102802643A (zh) * 2009-06-19 2012-11-28 阿奎赛公司 利用臭氧治疗炎性病症、心血管疾病和急性缺血性脑中风
AU2010260467A1 (en) * 2009-06-19 2012-02-09 Acquisci, Inc. Treatment of inflammatory disorders, cardiovascular diseases and acute ischemic brain stroke with ozone
US8639327B2 (en) 2010-04-29 2014-01-28 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8888699B2 (en) 2010-04-29 2014-11-18 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8620425B2 (en) 2010-04-29 2013-12-31 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
CN101829372A (zh) * 2010-05-11 2010-09-15 江苏中惠医疗科技股份有限公司 血细胞凋亡诱导系统
CN101843931A (zh) * 2010-05-19 2010-09-29 江苏中惠医疗科技股份有限公司 一种血细胞凋亡诱导方法
US8781582B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8718763B2 (en) 2011-01-19 2014-05-06 Medtronic, Inc. Vagal stimulation
US8706223B2 (en) 2011-01-19 2014-04-22 Medtronic, Inc. Preventative vagal stimulation
US8725259B2 (en) 2011-01-19 2014-05-13 Medtronic, Inc. Vagal stimulation
US8781583B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
ITMI20120338A1 (it) * 2012-03-06 2013-09-07 Dr Andrea Bignotti Preparato terapeutico e procedimento di preparazione di detto preparato terapeutico
CN113057965B (zh) * 2021-03-31 2023-07-04 河北康腾生物科技有限公司 一种活化焕颜美容液及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ249176A (en) * 1992-02-07 1996-11-26 Vasogen Inc Method of increasing concentration of nitric oxide in blood using ozone and uv radiation
US5980954A (en) * 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
US5591457A (en) * 1992-02-07 1997-01-07 Vasogen Inc Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human
PT1011696E (pt) 1997-09-12 2004-03-31 Vasogen Ireland Ltd Tratamento do stresse e precondicoes contra o stresse
US6136308A (en) * 1997-09-12 2000-10-24 Vasogen Ireland Limited Treatment of stress and preconditioning against stress
US6037346A (en) * 1997-10-28 2000-03-14 Vivus, Inc. Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6422462B1 (en) * 1998-03-30 2002-07-23 Morris E. Cohen Apparatus and methods for improved credit cards and credit card transactions
CA2271190A1 (en) 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure
AU2001243473A1 (en) * 2000-03-07 2001-09-17 American Express Travel Related Services Company, Inc. System for facilitating a transaction

Also Published As

Publication number Publication date
CZ20022402A3 (cs) 2003-01-15
DK1267897T3 (da) 2005-02-14
JP2003520244A (ja) 2003-07-02
NO20023267L (no) 2002-08-29
DE60107065T2 (de) 2005-04-07
HK1050847B (en) 2005-04-01
CN1173710C (zh) 2004-11-03
HK1050847A1 (en) 2003-07-11
US20060193835A1 (en) 2006-08-31
ES2232632T3 (es) 2005-06-01
EA200200767A1 (ru) 2002-12-26
EP1267897B1 (en) 2004-11-10
EP1267897A1 (en) 2003-01-02
CN1400906A (zh) 2003-03-05
BR0107705A (pt) 2002-11-19
WO2001052870A1 (en) 2001-07-26
US20030044390A1 (en) 2003-03-06
EA005011B1 (ru) 2004-10-28
ATE281839T1 (de) 2004-11-15
NO20023267D0 (no) 2002-07-05
US6572895B2 (en) 2003-06-03
AU773118B2 (en) 2004-05-20
TR200201822T2 (tr) 2003-01-21
PT1267897E (pt) 2005-02-28
AU2820801A (en) 2001-07-31
MXPA02007032A (es) 2003-09-22
ZA200205401B (en) 2003-07-07
KR100543413B1 (ko) 2006-01-20
CA2400801C (en) 2007-01-09
US7153649B2 (en) 2006-12-26
DE60107065D1 (de) 2004-12-16
KR20020073506A (ko) 2002-09-26
US20020051766A1 (en) 2002-05-02
NZ520083A (en) 2002-12-20
CA2296997A1 (en) 2001-07-18
IL150725A0 (en) 2003-02-12
CA2400801A1 (en) 2001-07-26

Similar Documents

Publication Publication Date Title
IL150725A0 (en) Treatment of congestive heart failure by pretreated autologous blood
EP1487431A4 (en) PREVENTING AND / OR TREATING CARDIOVASCULAR DISEASE AND / OR RELATED CARDIAC INSUFFICIENCY
MY113059A (en) Controlled-release dosage forms of azithromycin
BR0212252A (pt) Métodos para reduzir a hipertensão e a insuficiência cardìaca em um mamìfero
EP0933995B8 (en) Method of treating endothelial injury
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
WO2005048944A3 (en) Activatable photodynamic therapy agents
AU1617001A (en) Use of low-dose pdt to inhibit restenosis
AU2001236529A1 (en) Combination therapy for cancer
CZ20011642A3 (cs) Léčivo pro prevenci progrese aterosklerózy u savců
MXPA05005911A (es) Utilizacion del acido docosahexaenoico como sustancia activa para el tratamiento de la lipodistrofia.
IL159770A0 (en) Calcium salts with cytotoxic activity
NZ515173A (en) Treatment of hypersensitivity reaction disorders
RU97101420A (ru) Способ лечения тонзиллита
RU95105085A (ru) Способ воздействия на биологический объект
WO2001022976A3 (en) Combination of a statin and ex-vivo treated blood for treating artheroclerosis
AR061635A1 (es) Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos
De Angelis et al. Spontaneous clostridial myonecrosis after pregnancy–emergency treatment to the limb salvage and functional recovery: a case report
UA32153A (uk) Спосіб формування трансплантату для зведення на промежину при черевно-анальних резекціях прямої кишки
Starreveld et al. Radical choices in mastectomy [Letter and response]
UA31131A (uk) Спосіб прогнозування післяопераційного перебігу інфекційного ендокардиту
KR20000016317U (ko) 원적외선과 자장을 이용한 생리통 경감팬티
UA28928A (uk) Спосіб лікування гнійно-запальних захворювань м'яких тканин
UA36490A (uk) Спосіб лікування гнійно-септичних захворювань м'яких тканин

Legal Events

Date Code Title Description
VDSO Invalidation of derivated patent or utility model

Ref document number: 384853

Country of ref document: PL

VOID Decisions declaring the decisions on the grant of the patent lapsed